Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?
- 120 Downloads
Surgery, radioiodine (RAI) and antithyroid drugs remain the main treatments in use today to cure Graves’ disease, solitary toxic thyroid nodules and toxic multinodular goitre [1, 2]. The treatment selection depends on many factors, including the clinician’s and patient’s preferences, the availability of a skilled surgeon, cost and local limitations on the therapeutic use of radioisotopes. A survey conducted more than 15 years ago among North American thyroid specialists concerning the treatment of a hypothetical patient with Graves’ disease found that 69% chose RAI as the preferred treatment. In Europe and Japan, RAI is less popular, being chosen as first-line therapy by only 22% and 11% of thyroid specialists, respectively . It is worth noting that cost per “cure” has been calculated to be US $5,644 per patient who receives thionamides, $2,063 per patient given RAI and $9,826 per patient who undergoes thyroidectomy; the most cost-effective primary treatment modality for...
KeywordsHyperthyroidism Thyroid Volume Antithyroid Drug Hyperthyroid Patient Subclinical Hyperthyroidism
- 1.Treatment guidelines for patients with hyperthyroidism and hypothyroidism http://www.thyroid.org/professionals/publications/documents/GuidelinesHyperHypo_1995.pdf.
- 2.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism http://www.aace.com/pub/pdf/guidelines/hypo_hyper.pdf.
- 5.EANM procedure guideline for therapy with iodine-131 http://eanm.org/scientific_info/guidelines/gl_radio_ther_i131.php?navId=54.
- 6.Society of Nuclear Medicine procedure guideline for therapy of thyroid disease with iodine-131 (sodium iodide) http://interactive.snm.org/docs/Therapy%20of%20Thyroid%20Disease%20with%20Iodine-131%20v2.0.pdf.
- 16.Muhammad W, Faaruq S, Hussain A, Kakakhail MB, Fatmi S, Matiullah. Quantitative analysis of the factors responsible for over or under dose of 131I therapy patients of hyperthyroidism. Radiat Prot Dosimetry. 2007 May 27; [Epub ahead of print].Google Scholar
- 18.Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007 Jun 13; [Epub ahead of print].Google Scholar
- 19.Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council Directive 97/43 EURATOM 1997.Google Scholar